MiNK Therapeutics 15min chart sees KDJ Death Cross and Bearish Marubozu signal.

MiNK Therapeutics's 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu, indicating a shift in momentum towards the downside. This suggests a potential further decrease in the stock price, with sellers dominating the market. It is likely that the bearish momentum will continue.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, has announced an update to its virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The webcast introduces a new virtual format designed to provide an engaging experience for attendees and includes an updated participation link [1]. The event will cover a strategic and financial overview, updates on the Zydus partnership, recent clinical data for Botensilimab (BOT) and Balstilimab (BAL), and an overview of the Phase 3 BATTMAN study in metastatic colorectal cancer (CRC). Additionally, the session will feature a spotlight on MiNK Therapeutics, a significant stakeholder of Agenus, and upcoming milestones across the portfolio. The webcast will conclude with a live Q&A session [1].

Key Updates and Speakers:
- Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus, will provide an overview of the company's strategic and financial status.
- Richard M. Goldberg, MD, Chief Development Officer of Agenus, will discuss the Zydus partnership and recent clinical updates for BOT and BAL.
- Nicholas C. DeVito, MD, Assistant Professor of Medical Oncology at Duke University, will share insights on patient needs and CRC studies.
- Chris O'Callaghan, DVM, MSc, PhD, Senior Investigator at Canadian Cancer Trials Group (CCTG), will provide an update on the Phase 3 BATTMAN study.
- Jen Buell, PhD, Chief Executive Officer of MiNK Therapeutics, will highlight the company's role and significance within Agenus' portfolio.

Clinical Programs and Partnerships:
Agenus' pipeline includes Botensilimab, a multifunctional, human Fc enhanced CTLA-4 blocking antibody, and Balstilimab, a novel PD-1 blocking antibody. Botensilimab has shown clinical responses across nine metastatic, late-line cancers, with approximately 1,200 patients treated in phase 1 and 2 trials [1]. Balstilimab has been evaluated in 900 patients and demonstrated clinical activity and favorable tolerability profiles in several tumor types [1].

Forward-Looking Statements:
The press release includes forward-looking statements regarding the clinical programs, expected trial initiations, regulatory plans, and potential benefits of combination therapies. These statements are subject to risks and uncertainties, including those described in Agenus' most recent annual report [1].

Investor and Media Contact Information:
- Investors: 917-362-1370 | investor@agenusbio.com
- Media: 781-674-4422 | communications@agenusbio.com

References:
[1] https://www.morningstar.com/news/business-wire/20250826512064/update-agenus-aug-27-stakeholder-webcasttransformative-io-updates-botbal-data-battman-preview-zydus-partnership-momentum-and-mink-spotlight
[2] https://www.marketscreener.com/news/agenus-aug-27-stakeholder-webcasta-transformative-io-updates-bot-bal-data-battman-preview-zydus-ce7c50d9da8bf12d